World Health

For Developing Countries

   Help  by CIDPUSA.org

 
Home
Medical Devices
Medical Protocols
Pharma Development
Stroke prevention
Skin diseases prevention
Alzheimer prevention
Heart Disease prevention
Aids treatment
About Us
 E-Book
Infectious diseases
Autoimmune diseases
National Diet Management
National chemical control
National pollution control

Summer Sun Benefits  

Ear Infections 

Cod Liver Oil 

Cosmetics

Toxic Household Chemicals  Toxins affects generations  

Vitamin-E in Heart disease

Vitamin-D in Heart disease

Fat lowering Diet

Kamut

Homocysteine Lowering diet

 

 

World Health for underdeveloped and  developing countries         
   Welcome to the CIDPUSA  International Foundation against autoimmune disorders   
 
 



 CIDP in childhood

Pain Med. 2002 Jun;3(2):119-27.

Human pooled immunoglobulin in the treatment of chronic pain syndromes.
Goebel A, Netal S, Schedel R, Sprotte G.
Klinik fur Anaesthesiologie, University Wurzburg, Wurzburg, Germany.

Objective. To examine the use of intravenous immunoglobulin (IVIG) in chronic pain. Design. A prospective multiple-dose, open-label cohort study in 130 consecutive patients who suffered from 12 chronic pain syndromes. The largest symptom groups were (number of patients): Fibromyalgia (48); Spinal pain (20); Complex regional pain syndrome (CRPS, 11); Peripheral neuropathic pain (12); and Atypical odontalgia or atypical facial pain (11). All patients had insufficient pain relief with established treatments. Pain relief was recorded using average pain intensity values as documented in standardized diaries. A specific treatment protocol was developed, and patients were enrolled over a 36-month period. Results. Overall, 20% of patients had>70% pain relief and 27.7% of patients reported relief between 25% and 70%. Six patients (4.6%) had moderately increased pain levels for a duration of up to 9 weeks. Good relief, of more than 70%, was found in all major symptom groups. Patients with pain of short duration (<2 years) reported high relief rates (33.8% of patients in this group reported relief openface>70%). No serious adverse events were reported. Conclusions. IVIG may be effective in patients suffering from chronic pain. Controlled studies are needed to evaluate the efficacy of IVIG in these patients. Patients with a good response to IVIG may be models for the study of neuroimmune interactions in chronic pain.

PMID: 15102158 [PubMed - in process]


Childhood chronic inflammatory demyelinating polyneuropathy.
Nevo Y.
The Institute for Child Development, Division of Pediatrics, Dana Children's Hospital, Sackler School of Medicine, Tel Aviv University, Israel.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic disorder of the peripheral nervous system with sensory and motor involvement, and insidious onset over a period of months. In children and adults, both proximal and distal muscles are affected. Muscle stretch reflexes are absent or depressed. Laboratory findings include elevated cerebrospinal fluid protein with no increase of mononuclear cells. Electrophysiological and pathological studies show evidence of demyelination. No control studies of the efficacy of immunomodulating therapy in childhood CIDP are available. However, several studies have indicated clinical improvement after treatment with prednisolone, plasmapheresis and intravenous immunoglobulin, but disappointing results with other immunosuppressive agents. While some children have a monophasic course, with complete recovery, others have a protracted course, with either a slowly progressive or a relapsing-remitting course, resulting in prolonged morbidity and disability.

PMID: 10726588 [PubMed - indexed for MEDLINE]
 

Please continue to next page

.
Return to Bechets mainpage

CIDPUSA